Applied DNA Sciences ($APDN@US), a leader in PCR-based DNA manufacturing technologies, plans to introduce its Linea 2.0 Covid-19 Assay, its Covid-19 diagnostic strategy in response to the emergence of the Omicron variant. The company will submit its validation data to the New York State Department of Health in the next few days. The new RT-PCR assay kit builds on the company’s established Covid-19 line of diagnostics and is intended for the qualitative detection of nucleic acid from the new strain of coronavirus in respiratory specimens. The test is intended for use with anterior nasal swab specimens that are self-collected in the presence of a healthcare professional from individuals without symptoms. Applied DNA shares were up 53.60% at $8.14 during premarket today.
Category
🗞
News